Alzheimer’s & Parkinson’s Drug Development Summit 2026
Trailhead Biosystems
February 3-5, 2026
Boston, MA
Presentation: Feb 4, 12:20 pm
Explore Elevate's capabilities
We have all the tools you need to run an effective marketing strategy
Content creation
Write a brief description of the product's capabilities
Analytics and reporting
Write a brief description of the product's capabilities
Messaging
Write a brief description of the product's capabilities
Integrations
Write a brief description of the product's capabilities
Automation and workflows
Write a brief description of the product's capabilities
Campaign scheduling
Write a brief description of the product's capabilities
AI Agents
Write a brief description of the product's capabilities
Cross channel distribution
Write a brief description of the product's capabilities
Trailhead Presentation
The Need for High-Purity A9 Dopaminergic Neurons within Parkinson's Disease models
Wednesday, February 4 - 12:20 pm | Track One
- Understand the biological significance of A9 vs. A10 dopaminergic neuron subtypes in Parkinson’s disease
- Learn how HD-DoE technology enables targeted development of A9 neurons with desired phenotypic profiles
- Review of key phenotypic and functional QC benchmarks
- Discussion of recommended use cases and applications in discovery and disease modeling
About the Presenter
Dr. Luke Bury is a stem cell biologist at Trailhead Biosystems with expertise in the differentiation of human induced pluripotent stem cells via 2D and 3D cell culture. Currently developing differentiation and manufacturing protocols as well as functionality assays for a variety of ectoderm-derived cells, including glial cells and multiple neuronal subtypes of forebrain and midbrain regions.